Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there's a catch.
Compass quarterly and full-year loss increases marginally. End-of-year cash position of $273.2 million. Strong results in Phase IIb study.
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).
Optimi Health announces the launch of six nootropic supplements derived from functional mushrooms.
Spiritual journey or clinical therapy? What does the future of psychedelic medicine look like?
Pharmather announces a method of use and composition of matter patent from the USPTO for its proprietary ketamine formulation, KETABET(TM).
Optimi Health's subsidiary has been named an approved supplier of psilocybin for Health Canada's SAP access program.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now